TZU-YI WANG: Open Payments
NPI 1346773819 · MODESTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,111 in 17 payments from 8 companies in 2025. Trend: 2023 $686 · 2024 $1,248 · 2025 $1,111
Food & beverage: $1,111
| Company | Payments | Amount |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 3 | $265 |
| Novo Nordisk Inc | 4 | $237 |
| Madrigal Pharmaceuticals | 3 | $202 |
| Corcept Therapeutics | 1 | $118 |
| Lilly USA, LLC | 2 | $107 |
| BETA BIONICS, INC. | 1 | $89 |
| AstraZeneca Pharmaceuticals LP | 1 | $55 |
| Dexcom, Inc. | 2 | $39 |
Products named: Yorvipath, REZDIFFRA, Korlym, iLet Bionic Pancreas, Ozempic, ZEPBOUND, MOUNJARO, Dexcom G6 Transmitter.
Industry payments across CA — which companies pay providers there.
